Deals channel feed

Ab­b­Vie's $10B Im­muno­Gen deal was won by pay­ing $7 a share over a ri­val bid­der's of­fer, SEC fil­ings show

Last year

Bris­tol My­ers bets on neu­ro­science surge with $14B Karuna cash ac­qui­si­tion

Last year
Pharma

J&J buys eye dis­ease gene ther­a­py from MeiraGTx, giv­ing the biotech the cash in­fu­sion it was seek­ing

Last year
Cell/Gene Tx

Lil­ly part­ners with start­up Fau­na Bio to see if a squir­rel’s hi­ber­na­tion could lead to new obe­si­ty drugs

Last year
Startups
Pharma

Bris­tol My­ers gets reg­u­la­to­ry clear­ance to close Mi­rati deal as FTC in­creas­es pres­sure on phar­ma M&A

Last year
Pharma

GSK se­cures an­oth­er ex-Chi­na ADC deal with Han­soh Phar­ma with $185M up­front

Last year
China

Why 2023 was the year of un­so­licit­ed ac­qui­si­tion bids — and why next year like­ly won’t be

Last year
In Focus

Blue­bird in fundrais­ing mode: A $150M pub­lic of­fer­ing and a deal to get cash ear­ly from gene ther­a­py sales

Last year
Financing

Com­pu­gen se­cures li­cens­ing deal with Gilead for IL-18 pro­tein an­ti­body can­cer pro­gram, with $60M up­front

Last year
R&D

Io­n­is di­vests com­mer­cial EU rights for rare dis­ease can­di­date to Ot­su­ka for $65M up­front

Last year
R&D

Organon adds Eli Lil­ly mi­graine meds to wom­en's health port­fo­lio in Eu­rope

Last year
Pharma

Pfiz­er picks up ear­ly-stage ADC can­di­date cleared for sol­id tu­mor tri­als

Last year

'Won­der­ful Christ­mas gift': Fed's sur­prise rate-cut plan springs hope of 2024 biotech mar­ket re­bound

Last year
Financing
Pharma

Did the FTC have a good rea­son to block the Sanofi-Maze deal?

Last year
Pharma

No­vo Nordisk to boost oral GLP-1 man­u­fac­tur­ing via $92.5M buy for Alk­er­mes’ Ire­land fa­cil­i­ty

Last year
Manufacturing

Pathos AI makes suc­cess­ful takeover bid for Rain On­col­o­gy

Last year

Ed­i­tas Med­i­cine pads run­way with $50M up­front from Ver­tex for Cas9 li­cense

Last year
Cell/Gene Tx

Icosavax buy­out caps As­traZeneca’s long search for a vac­cine plat­form

Last year
Pharma

Mer­ck ex­tends ADC push by lend­ing a hand to C4 with small up­front for pro­tein de­grad­er work

Last year
Pharma

Pfiz­er to com­plete Seagen ac­qui­si­tion Thurs­day, An­gela Hwang to de­part amid ex­ec­u­tive shuf­fle

Last year
Pharma

Bris­tol My­ers bags Sys­tIm­mune’s lung can­cer drug for $800M up­front in its third ADC-fo­cused pact of 2023

Last year
R&D

As­traZeneca plunks down $800M+ up­front to buy vac­cine de­vel­op­er Icosavax and chal­lenge Pfiz­er, GSK in RSV

Last year

FTC ex­pands phar­ma scruti­ny to ear­ly-stage deals, forc­ing Sanofi to drop Pompe dis­ease part­ner­ship with Maze

Last year

Van­da buys J&J's mul­ti­ple scle­ro­sis drug Pon­vory for $100M

Last year
Pharma
First page Previous page 23242526272829 Next page Last page
A service from the Financial Times